Literature DB >> 19169681

Posttherapeutic (131)I SPECT-CT offers high diagnostic accuracy when the findings on conventional planar imaging are inconclusive and allows a tailored patient treatment regimen.

S Kohlfuerst1, I Igerc, M Lobnig, H J Gallowitsch, I Gomez-Segovia, S Matschnig, J Mayr, P Mikosch, M Beheshti, P Lind.   

Abstract

PURPOSE: The purpose of this prospective study was to determine the diagnostic impact and influence on patient treatment of posttherapeutic (131)I SPECT-CT when the findings on planar posttherapeutic whole-body scintigraphy (ptWBS) were inconclusive.
MATERIALS AND METHODS: A total of 53 SPECT-CT scans were performed in 41 patients with thyroid cancer after high-dose (131)I therapy (2.944 to 7.526 GBq (131)I) because of diagnostic uncertainty on ptWBS. Physiological uptake in the salivary glands, gastric mucosa, gut, nasal mucosa, urinary tract and liver were considered to be normal. Any other foci of increased (131)I uptake, except iodine uptake clearly located in the thyroid bed, were considered to be abnormal. The data were evaluated on a lesion and a patient basis.
RESULTS: Regarding neck lesions, SPECT-CT provided a diagnostic impact in 26/90 lesions (28.9%) and confirmed the diagnosis in 64/90 lesions (71.1%). On a patient basis, SPECT-CT changed N status in 12/33 patients (36.4%), provided a diagnostic impact in 21/33 patients (63.6%) and led to a treatment change in 8/33 patients (24.2%). Regarding lesions distant from the neck, SPECT-CT confirmed the diagnosis in 62/71 lesions (87.3%) and had a diagnostic impact in 9/71 lesions (12.7%). On a patient basis, SPECT-CT changed M status in 4/19 patients (21.1%), had a diagnostic impact in 14/19 patients (73.7%) and led to a treatment change in 2/19 patients (10.5%). Considering all patients, SPECT-CT led to a treatment change in 10/41 patients (24.4%).
CONCLUSION: Integrated SPECT-CT is a useful tool, especially in cases of diagnostic uncertainty and helps to individualize patient management.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19169681     DOI: 10.1007/s00259-008-1044-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  29 in total

1.  A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group.

Authors:  D P Byar; S B Green; P Dor; E D Williams; J Colon; H A van Gilse; M Mayer; R J Sylvester; M van Glabbeke
Journal:  Eur J Cancer       Date:  1979-08       Impact factor: 9.162

2.  Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients.

Authors:  Ian D Hay; Geoffrey B Thompson; Clive S Grant; Eric J Bergstralh; Catherine E Dvorak; Colum A Gorman; Megan S Maurer; Bryan McIver; Brian P Mullan; Ann L Oberg; Claudia C Powell; Jon A van Heerden; John R Goellner
Journal:  World J Surg       Date:  2002-05-21       Impact factor: 3.352

3.  Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practice.

Authors:  Martin Schlumberger; Furio Pacini; Wilmar M Wiersinga; Antony Toft; Johannes W A Smit; Franco Sanchez Franco; Peter Lind; Edward Limbert; Barbara Jarzab; François Jamar; Leonidas Duntas; Ohad Cohen; Gertrud Berg
Journal:  Eur J Endocrinol       Date:  2004-11       Impact factor: 6.664

4.  Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis.

Authors:  T P Links; K M van Tol; P L Jager; J Th M Plukker; D A Piers; H M Boezen; R P F Dullaart; E G E de Vries; W J Sluiter
Journal:  Endocr Relat Cancer       Date:  2005-06       Impact factor: 5.678

5.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; S M Jhiang
Journal:  Am J Med       Date:  1994-11       Impact factor: 4.965

6.  Visualization of nasolacrimal drainage system after radioiodine therapy in patients with thyroid cancer.

Authors:  Harumi Sakahara; Shuhei Yamashita; Kazunori Suzuki; Michiko Imai; Takashi Kosugi
Journal:  Ann Nucl Med       Date:  2007-11-26       Impact factor: 2.668

Review 7.  Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective.

Authors:  Martin Schlumberger; Gertrud Berg; Ohad Cohen; Leonidas Duntas; François Jamar; Barbara Jarzab; Eduard Limbert; Peter Lind; Furio Pacini; Christoph Reiners; Franco Sánchez Franco; Anthony Toft; Wilmar M Wiersinga
Journal:  Eur J Endocrinol       Date:  2004-02       Impact factor: 6.664

8.  Impact of 131I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma.

Authors:  K Tharp; O Israel; J Hausmann; L Bettman; W H Martin; M Daitzchman; M P Sandler; D Delbeke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-06-19       Impact factor: 9.236

9.  Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma.

Authors:  S I Sherman; E T Tielens; S Sostre; M D Wharam; P W Ladenson
Journal:  J Clin Endocrinol Metab       Date:  1994-03       Impact factor: 5.958

10.  False-positive radioiodine whole-body scan in thyroid cancer patients due to unrelated pathology.

Authors:  S M Bakheet; M M Hammami
Journal:  Clin Nucl Med       Date:  1994-04       Impact factor: 7.794

View more
  20 in total

Review 1.  SPECT/CT and tumour imaging.

Authors:  Gad Abikhzer; Zohar Keidar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-08-29       Impact factor: 9.236

2.  Endocrine radionuclide scintigraphy with fusion single photon emission computed tomography/computed tomography.

Authors:  Ka-Kit Wong; Arpit Gandhi; Benjamin L Viglianti; Lorraine M Fig; Domenico Rubello; Milton D Gross
Journal:  World J Radiol       Date:  2016-06-28

3.  Less is more: reconsidering the need for regular use of diagnostic whole body radioiodine scintigraphy in the follow-up of differentiated thyroid cancer.

Authors:  Christian Pirich; Gregor Schweighofer-Zwink
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02-02       Impact factor: 9.236

Review 4.  The role of nuclear medicine in differentiated thyroid cancer.

Authors:  Susanne Kohlfürst
Journal:  Wien Med Wochenschr       Date:  2012-07-20

Review 5.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

6.  Differentiated thyroid carcinoma: Incremental diagnostic value of 131I SPECT/CT over planar whole body scan after radioiodine therapy.

Authors:  Valentina Zilioli; Alessia Peli; Maria Beatrice Panarotto; Giancarlo Magri; Ahmed Alkraisheh; Christiane Wiefels; Carlo Rodella; Raffaele Giubbini
Journal:  Endocrine       Date:  2016-09-29       Impact factor: 3.633

7.  SPECT/CT imaging in children with papillary thyroid carcinoma.

Authors:  Hwa-Young Kim; Michael J Gelfand; Susan E Sharp
Journal:  Pediatr Radiol       Date:  2011-05-24

Review 8.  Value of ¹³¹I SPECT/CT for the evaluation of differentiated thyroid cancer: a systematic review of the literature.

Authors:  Yan-Li Xue; Zhong-Ling Qiu; Hong-Jun Song; Quan-Yong Luo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-12-15       Impact factor: 9.236

9.  Five months' follow-up of patients with and without iodine-positive lymph node metastases of thyroid carcinoma as disclosed by (131)I-SPECT/CT at the first radioablation.

Authors:  Daniela Schmidt; Rainer Linke; Michael Uder; Torsten Kuwert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-11-20       Impact factor: 9.236

Review 10.  SPECT/CT in the Treatment of Differentiated Thyroid Cancer.

Authors:  Sang-Woo Lee
Journal:  Nucl Med Mol Imaging       Date:  2017-02-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.